12 December 2017 EMA/779846/2017 International Affairs

2nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency An introduction for international regulators, NGOs and academia 08-09 March 2018 London, UK Chair: Dr Agnès Saint-Raymond

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5505 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

Day 1 - Thursday 8 March 2018 Time

Module / Topics

08:4509:00

Opening remarks and Official welcome

09:0010:00

01 - Setting the scene: Introduction to the EU Regulatory Network (including committees)

10:00– 11:00



The EU and the EU Regulatory Network



The EMA role

02 - Engagement with stakeholders 

Patients, Health Care Professionals and Academia



Pharmaceutical industry

11:0011:30 11:3013:00

Coffee break 03 - Early engagement on medicine development: Scientific Advice, ITF and PRIME 

Scientific advice: what it is and how to approach it



Qualification of novel methodologies: a pillar to effective translation of research



Innovation Task Force: a safe harbour to discuss innovation



PRIME: support to academia pursuing unmet medical needs

13:00– 14:00 14:0015:00

Lunch 04 - ATMPs 

Advanced therapy classification



Support for advanced-therapy developers

15:0015:30 15:3016:30

16:3017:30 17:30– 21:30

Coffee break 05 - Clinical trials in the EU 

CT authorisation in the EU



EU CT legislation revision

06 - Hot topic: EMA Support to Innovation

Group photo and Networking event

2nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency EMA/779846/2017

Page 2/3

Day 2 - Friday 9 March 2018 Time

Module / Topics for discussion

08:30– 10:30

07 - Benefit Risk assessment and good regulatory practice workshop 

Use of experts, assessment teams and peer review



Standard of evidence and guidelines



Types of approvals: conditional approval, accelerated assessment, adaptive pathways, post-approval commitments



Medicinal products lifecycle



Health Technology Assessment (HTA) bodies and reimbursement

11:0011:30 11:3012:30

Coffee break 08 – Dealing with specific populations and types of products 

Paediatric medicines, orphan medicines



Generics, biosimilars and herbals

12:30– 13:30

Lunch

13:3015:00

09 - Good practice and inspections 

GMP supervision of manufacturers and inspections and dealing with quality defects



GCP, GLP and GVP supervision and inspections

15:0015:30 15:3017:00

17:0018:00

18:0018:15

Coffee break 10 - Patient safety and Pharmacovigilance 

Overview of the EU Ph.Vig. systems



Signal detection and management



Eudravigilance

11 - International Cooperation 

EU Network international strategy



Bilateral cooperation: CAs, clusters and MRAs



Multilateral cooperation (ICH, ICMRA, IPRF etc.) and EU-M4All

Closing remarks

2nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency EMA/779846/2017

Page 3/3

2nd International Awareness Session - European Medicines Agency

Dec 12, 2017 - Medicines Agency. EMA/779846/2017. Page 2/3. Day 1 - Thursday 8 March 2018. Time. Module / Topics. 08:45-. 09:00. Opening remarks and Official welcome. 09:00-. 10:00. 01 - Setting the scene: Introduction to the EU Regulatory. Network (including committees). • The EU and the EU Regulatory Network.

187KB Sizes 5 Downloads 258 Views

Recommend Documents

Enpr-EMA awareness webinar - European Medicines Agency
Nov 15, 2016 - conference window. Please ensure ... full international format and click Join to receive a call from the system (you will be automatically muted).

Report - European Medicines Agency
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.

Human Medicines Highlights Newsletter - European Medicines Agency
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a ... Withdrawal of applications for new medicines .... fifth annual regulatory conference on optimising the development of advanced therapies to.

Human Medicines Highlights Newsletter - European Medicines Agency
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.

Agenda - European Medicines Agency veterinary medicines ...
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung

Registration form - European Medicines Agency
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.

Registration form - European Medicines Agency
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.

Agenda - European Medicines Agency - europa.eu
Jun 18, 2018 - 27. 7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of .... 5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one, EMA/OD/031/10 Glutathione-pegylated ...... Abbreviations / Acronyms.

Human Medicines Highlights Newsletter - European Medicines Agency
Implant used to help new bone develop in patients with spinal disc problems and leg fractures .... E-mail [email protected] Website www.ema.europa.eu.

Finasteride - European Medicines Agency - europa.eu
Apr 25, 2018 - Page 2/8. Product Name (in authorisation country). MRP/DCP. Authorisation number. National Authorisation Number. MAH of product in the.